I buy Peter's argument that something was probably lacking in their initial submission and the FDA will require something else which will require a resubmission (in addition to more work). With the back-and-forth I am hoping it is more along the line of years. Based on how long it took Momenta to provide additional immunogenicity data and get their approval I think 1-2 years would be needed for the back and forth and that is why I refer to the time frame as "later".
That being said I hope I am wrong and Dew collects two nice free Dinners :-).
Market Data 
Markets 
AI
